Source
Author: unknown
Eli Lilly to buy genetic medicine developer Akouos for $487 million [Deals Market Headlines | Breaking Stock Market News | Reuters]
Related Posts
AstraZeneca Shares Tumble on Reports of $400 Billion Bristol Myers Squibb Merger Talks
AstraZeneca PLC (LON: AZN) shares fell as much as 7% in London trading on Monday, August 3, 2026, following reports that the British pharmaceutical giant has held preliminary discussions regarding a...
Biogen Shifts M&A Strategy as Apellis Acquisition Pushes Revenue Above Analyst Expectations
CAMBRIDGE, Mass. — Biogen Inc. (NASDAQ: BIIB) has signaled a definitive pivot in its capital allocation strategy following a blockbuster second quarter that saw the company swing from a projected...
Bayer Bolsters Ophthalmology Portfolio with $2.45 Billion Acquisition of Perfuse Therapeutics
TL;DR Bayer AG announced on May 6, 2026, its acquisition of Perfuse Therapeutics for up to $2.45 billion, including a $300 million upfront payment and $2.15 billion in milestones. The deal secures...
UCB Acquires Candid Therapeutics for $2.2 Billion in High-Stakes Bet on ‘Immune Reset’
TL;DR Brussels-based biopharma UCB will acquire Candid Therapeutics for up to $2.2 billion, comprised of a $2.0 billion upfront cash payment and $200 million in milestones. The deal centers on...